Pharmaceuticals

Trulieve Cannabis Corp.

Trulieve Cannabis Corp. released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 286.75 M (forecast USD 285.95 M), actual EPS USD 0.0124

Trulieve Reports Q1 2026 Earnings

Trulieve Cannabis Corp. to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 284.48 M

Trulieve Submits Application for Medical Marijuana Business Registration

Trulieve Cannabis Corp. released FY2025 Q4 earnings on February 26 Pre-Market (EST), actual revenue USD 293.1 M (forecast USD 296.78 M), actual EPS USD -0.2237

Trulieve Cannabis Corp. released FY2025 earnings on February 26 Pre-Market (EST), actual revenue USD 1.181 B (forecast USD 1.185 B), actual EPS USD -0.6082

Trulieve Reports Q4 Revenue Down But Gross Margin Stable

Trulieve Cannabis Corp. to Release FY2025 Q4 Earnings on February 26, Pre-Market EST; Forecast Revenue USD 297.46 M

Trulieve Cannabis Corp. Praises Rescheduling of Marijuana

Trulieve Cannabis Completes $140 Million Private Placement

Trulieve Opens New Pharmacy in Ohio

Trulieve Cannabis Corp Receives Conditional Approval for Pharmaceutical Distributor License in Texas

Haywood Analyst Maintains Buy Rating on Trulieve Cannabis

Trulieve Cannabis Corp. released FY2025 9 Months earnings on November 5 Pre-Market EST, actual revenue USD 888.03 M, actual EPS USD -0.3843

Trulieve Cannabis Corp. released FY2025 Q3 earnings on November 5 Pre-Market (EST), actual revenue USD 288.2 M (forecast USD 287.46 M), actual EPS USD 0

Trulieve Cannabis Corp. to Release FY2025 Q3 Earnings on November 5, Pre-Market EST, Forecast Revenue USD 287.91 M

Trump Considering Rescheduling Marijuana

Trulieve Cannabis Corp. released FY2025 Semi-Annual earnings on August 6 Pre-Market EST, with actual revenue of USD 599.85 M and EPS of USD -0.244

Trulieve Cannabis Corp. released FY2025 Q2 earnings on August 6 Pre-Market (EST), actual revenue USD 302.09 M (forecast USD 298 M), actual EPS USD -0.072

Trulieve Cannabis Corp. Reports Strong Q2 Results

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

TCNNF

TLRY

CURLF

CRON

GTBIF

MSOS

A new report from the Global Cannabis Network Collective and Whitney Economics highlights pricing compression as a key indicator of cannabis market maturity. It analyzes how expanding supply and evolving regulations impact pricing across emerging markets in Europe and Latin America. The report emphasizes that while initial market prices may be high, sustained downward pressure is common as markets mature. It also discusses the influence of regulatory frameworks and consumer behavior on pricing stability and operator profitability, providing insights for investors and policymakers.

prnewswire

Tilray Brands

Aurora Cannabis

Curaleaf Holdings, Inc.

Canopy Growth

Cronos

Green Thumb Industries Inc.

AdvisorShares Pure US Cannabis ETF

Amplify Alternative Harvest ETF

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

CRLBF

IIPR

VICE

The recent rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act marks a significant regulatory shift for the U.S. cannabis industry. CEOs from major cannabis companies highlight key implications for investors, including improved cash flow, better access to banking services, potential uplisting on exchanges, and increased interest from institutional investors. However, there are concerns about overly optimistic timelines for recreational cannabis rescheduling, as support for such changes remains limited.

CabotWealthNetwork

Cresco Labs Inc.

Innovative Industrial Properties

AdvisorShares Vice - ETF

Here’s What “Rescheduling” Really Means for Investors

Trulieve Announces Proposed Domestication from British Columbia to Delaware | TCNNF Stock News

StockTitan

Trulieve Announces Proposed Domestication from British Columbia to Delaware | TCNNF Stock News

Analyst Neal Gilmer from Haywood has reiterated a Buy rating on Trulieve Cannabis, maintaining a price target of C$19.00. This decision is based on the company's strong profitability and cash generation, despite modest revenue pressure. Trulieve exceeded revenue expectations in Q1/26, delivered solid adjusted EBITDA, and maintained robust margins. The company's extensive retail presence and brand strength, along with a healthy cash balance, position it well for future growth opportunities.

Tip Ranks

Analyst Reiterates Buy on Trulieve, Maintains $19 Price Target on Strong Profitability and Cash Generation

Trulieve Cannabis reported profitable Q1 2026 results with $287 million in revenue, a 59% gross margin, and a net income of $2 million. The company expanded its Florida retail network and strengthened liquidity with a $60 million private placement. Following the Trump Administration's rescheduling of medical marijuana to Schedule III, Trulieve is filing DEA registration applications for 206 dispensaries. Analysts rate TRUL stock as a Buy with a C$15.00 price target, though concerns about valuation and regulatory risks remain.

Trulieve Cannabis Posts Profitable Q1 2026, Expands Footprint

Earnings Watch

Trulieve Cannabis Corp. | 10-Q: FY2026 Q1 Revenue: USD 286.75 M

Trulieve Cannabis Corp.(TCNNF.US)

07:05 ETNew Global Cannabis Report from GCNC and Whitney Economics Examines How Pricing Compression Reshapes Emerging Markets

Here’s What “Rescheduling” Really Means for Investors

Trulieve Announces Proposed Domestication from British Columbia to Delaware | TCNNF Stock News

Analyst Reiterates Buy on Trulieve, Maintains $19 Price Target on Strong Profitability and Cash Generation

Trulieve Cannabis Posts Profitable Q1 2026, Expands Footprint

Trulieve Cannabis Corp. | 10-Q: FY2026 Q1 Revenue: USD 286.75 M